Australian Clinical Labs is a diagnostics & research business based in Australia. Australian Clinical Labs shares (ACL) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Australian Clinical Labs has a trailing 12-month revenue of around $697.1 million. If you're looking to buy shares, check out the steps below.
Our top pick for
Low costs
Our top pick for
Education & learning
Our top pick for
Australian stocks
| 52-week range | $2.47 - $3.7053 |
|---|---|
| 50-day moving average | $2.6916 |
| 200-day moving average | $3.1766 |
| Target price | $3.58 |
| PE ratio | 14.25 |
| Dividend yield | $0.14 (5.36%) |
| Earnings per share (TTM) | $0.18 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$2.87
| 1 week (2023-11-30) | 9.54% |
|---|---|
| 1 month (2023-11-10) | 7.49% |
| 3 months (2023-09-08) | -4.65% |
| 6 months (2023-06-09) | -14.07% |
| 1 year (2022-12-09) | -7.42% |
|---|---|
| 2 years (2021-12-10) | -38.01% |
Valuing Australian Clinical Labs stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Australian Clinical Labs's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Australian Clinical Labs's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Australian Clinical Labs shares trade at around 14x recent earnings.
That's relatively low compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Australian Clinical Labs's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $78.5 million (£0.0 million).
The EBITDA is a measure of a Australian Clinical Labs's overall financial performance and is widely used to measure stock profitability.
| Revenue TTM | $697.1 million |
|---|---|
| Operating margin TTM | 8.69% |
| Gross profit TTM | $250.4 million |
| Return on assets TTM | 6.63% |
| Return on equity TTM | 17.79% |
| Profit margin | 5.15% |
| Book value | 0.86 |
| Market capitalisation | $526.8 million |
TTM: trailing 12 months
Dividend payout ratio: 107.69% of net profits
Recently Australian Clinical Labs has paid out, on average, around 107.69% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 5.36% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Australian Clinical Labs shareholders could enjoy a 5.36% return on their shares, in the form of dividend payments. In Australian Clinical Labs's case, that would currently equate to about A$0.14 per share.
Australian Clinical Labs's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 14 September 2023 (the "ex-dividend date").
Over the last 12 months, Australian Clinical Labs's shares have ranged in value from as little as $2.47 up to $3.7053. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Australian Clinical Labs's is 1.153. This would suggest that Australian Clinical Labs's shares are a little bit more volatile than the average for this exchange and represent, relatively speaking, a slightly higher risk (but potentially also market-beating returns).
Australian Clinical Labs Limited provides pathology services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offers its service to private and public hospitals. Australian Clinical Labs Limited was incorporated in 2020 and is headquartered in Clayton, Australia.
What you need to know about investing in Shein from Australia.
Looking for the best performing stocks in Australia? We update this list weekly.
If you're thinking of trading stocks with Tiger Brokers, check out our review of this online broker's fees, safety and pros and cons first.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Steps to owning and managing Caltex Australia shares from .
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
Learn about the money market and everyday consumer money market products.
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
Follow these tips to find the best share trading platform for you.
